Sutton G P, Blessing J A, Photopulos G, Berman M L, Homesley H D
Gynecologic Oncology Group, Philadelphia, PA 19107.
Cancer Chemother Pharmacol. 1990;26 Suppl:S55-8. doi: 10.1007/BF00685421.
Starting in July 1985, the Gynecologic Oncology Group conducted a series of phase II trials with ifosfamide/mesna in advanced or recurrent gynecologic malignancies. Previously untreated patients received 1.5 g/m2 i.v. ifosfamide daily for 5 days. Mesna was given i.v. q4h x 3 following ifosfamide; each dose was 20% of the daily ifosfamide dose. All patients with ovarian and 87% of those with cervical cancer had previously undergone platinum-based therapy. Because of the toxicity encountered in previously treated patients with ovarian carcinoma, the dose of ifosfamide was reduced to 1.2 g/m2 daily in all patients who had received prior chemo- or radiotherapy. In epithelial ovarian carcinoma, responses were observed in 8 (20.0%) of 41 evaluable patients, with 3 (7.0%) complete responses. Response duration was 2.1-20.3+ months, with a median of 6.9+ months. In squamous-cell carcinoma of the cervix, 3 (11.1%) of 27 evaluable patients showed partial responses of 1.8, 2.2, and 3.1 months' duration. Of 26 untreated patients with mixed mesodermal tumors of the uterus, 5 (19.2%) achieved complete and 3 (11.5%) showed partial responses, for an overall response rate of 30.7%. Response duration was 1.4(+)-8.6 months, with a median of 3.8 months. Toxicity included two deaths due to renal insufficiency and a third related to neurologic impairment. Hematologic toxicity was manageable. Ifosfamide/mesna has activity in a wide range of gynecologic malignancies.
从1985年7月开始，妇科肿瘤学组开展了一系列用异环磷酰胺/美司钠治疗晚期或复发性妇科恶性肿瘤的II期试验。未经治疗的患者静脉注射异环磷酰胺1.5 g/m²，每日1次，共5天。美司钠在异环磷酰胺后静脉注射，每4小时1次，共3次；每次剂量为每日异环磷酰胺剂量的20%。所有卵巢癌患者及87%的宫颈癌患者此前均接受过铂类治疗。由于既往接受治疗的卵巢癌患者出现了毒性反应，所有既往接受过化疗或放疗的患者，异环磷酰胺剂量减至每日1.2 g/m²。在上皮性卵巢癌中，41例可评估患者中有8例（20.0%）出现缓解，其中3例（7.0%）完全缓解。缓解持续时间为2.1 - 20.3 + 个月，中位时间为6.9 + 个月。在宫颈鳞状细胞癌中，27例可评估患者中有3例（11.1%）出现部分缓解，缓解持续时间分别为1.8、2.2和3.1个月。在26例未经治疗的子宫混合性中胚叶肿瘤患者中，5例（19.2%）完全缓解，3例（11.5%）部分缓解，总缓解率为30.7%。缓解持续时间为1.4(+) - 8.6个月，中位时间为3.8个月。毒性反应包括2例因肾功能不全死亡，第3例与神经功能损害有关。血液学毒性可控制。异环磷酰胺/美司钠对多种妇科恶性肿瘤有活性。
